On Nov. 22, 2022, the U.S. Food and Drug Administration issued an Emergency Use Authorization for the Lucira COVID-19 & Flu Test for use in a point-of-care setting.

The Lucira COVID-19 & Flu Test is the first molecular COVID-19 test authorized following collaboration with the National Institutes of Health Independent Test Assessment Program.